Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer

被引:28
作者
Qiu, Cheng-Zhi [1 ]
Wang, Chuan
Huang, Zhong-Xin
Zhu, Shi-Ze
Wu, You-Yi
Qiu, Lian-Long
机构
[1] Fujian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Quanzhou 362000, Fujian Province, Peoples R China
[2] Fujian Med Univ, Affiliated Union Hosp, Dept Oncol, Fuzhou 350001, Fujian Province, Peoples R China
[3] Fujian Med Univ, Affiliated Hosp 2, Dept Pathol, Quanzhou 362000, Fujian Province, Peoples R China
关键词
somatostatin receptor subtype; cell proliferation; apoptosis; p53; colorectal cancer; immunohistochemistry;
D O I
10.3748/wjg.v12.i13.2011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To study the SSTR1, 2, 3, 4, 5 expression and their relationships with clinico-pathological factors, cell proliferation, Bcl-2 and p53 expression in colorectal cancer cells. Methods: Immunohistochemical staining of five SSTR subtypes, Ki-67, Bcl-2 and p53 was performed by the standard streptavidin-peroxidase (SP) technique for the paraffin sections of 127 colorectal cancers. and expression of five SSTR subtypes in 40 specimens of normal colorectal mucosae was detected with the same method. Results: Positive staining for five SSTR subtypes was observed in colorectal cancer cells and normal colorectal mucosae. SSTR1 was the most predominant subtype in both colorectal cancer and normal colorectal mucosa, and the second was SSTR5 or SSTR2. As compared with normal colorectal mucosa, SSTR4 was more frequently expressed in colorectal cancer cells (2.5% vs 18.9%, P<0.05); the expression of SSTR2, 4, 5 in moderately to well differentiated colorectal adenocarcinoma was significantly higher than that in poorly differentiated ones (P<0.05), the SSTR1 expression in colorectal cancer with positive lymph node metastasis was significantly higher than that with negative lymph node metastasis (72.2% and 54.5%, P<0.05). In addition, in the ulcerative type of colorectal cancer, SSTR2 expression was obviously decreased (P<0.05); the correlation did not reach a statistical significance between the five SSTR subtypes expression and Dukes' stages (P>0.05), but the frequency of SSTR1 expression increased with Dukes' stage, while SSTR3 and SSTR5 expression decreased with Dukes' stage. Moreover, there was no correlation between expression of the five SSTR subtypes and other clinicopathological factors such as age, sex, tumor site, tumor depth, distant metastasis. The proliferative indexes in colorectal cancer cells with negative expression of SSTR2 and SSTR3 were significantly higher than that with positive expression (P<0.05). The Bcl-2 expression in colorectal cancer cells with positive expression of SSTR1, 2, 3, 5 was significantly lower than that with negative expression (P<0.05). There was no correlation between five SSTR subtypes and p53 expression. Conclusion: The most predominant SSTR subtype is SSTR1, and the second is SSTR2 or SSTR5. Five SSTR subtypes play different roles in the development of colorectal cancer. SSTR2 and SSTR3 can inhibit the proliferation and promote apoptosis of tumor cells. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:2011 / 2015
页数:5
相关论文
共 20 条
  • [1] Antiproliferative effect of somatostatin and analogs
    Bousquet, C
    Puente, E
    Buscail, L
    Vaysse, N
    Susini, C
    [J]. CHEMOTHERAPY, 2001, 47 : 30 - 39
  • [2] Buscail L, 1996, CANCER RES, V56, P1823
  • [3] Denzler B, 1999, CANCER, V85, P188, DOI 10.1002/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO
  • [4] 2-3
  • [5] Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts
    Du, Zhi-Yong
    Qin, Ren-Yi
    Xia, Wei
    Tian, Rui
    Kumar, Manoj
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (04) : 516 - 520
  • [6] Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis
    Guillermet, J
    Saint-Laurent, N
    Rochaix, P
    Cuvillier, O
    Levade, T
    Schally, AV
    Pradayrol, L
    Buscail, L
    Susini, C
    Bousquet, C
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) : 155 - 160
  • [7] The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
    Hejna, M
    Schmidinger, M
    Raderer, M
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (05) : 653 - 668
  • [8] Molecular signaling of somatostatin receptors
    Lahlou, H
    Guillermet, J
    Hortala, M
    Vernejoul, F
    Pyronnet, S
    Bousquet, C
    Susini, C
    [J]. GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 : 121 - 131
  • [9] sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation
    Lahlou, H
    Saint-Laurent, N
    Estève, JP
    Eychène, A
    Pradayrol, L
    Pyronnet, S
    Susini, C
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (41) : 39356 - 39371
  • [10] Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae
    Laws, SAM
    Gough, AC
    Evans, AA
    Bains, MA
    Primrose, JN
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (03) : 360 - 366